澳门大阳城122.ccapp官方下载

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma.

Carcinogenesis. 2015; 
Zhang HF,,, Alshareef A, Wu C, Jiao JW,, Sorensen PH, Lai R, Xu LY, Li EM.
Products/Services Used Details Operation
Gene Synthesis Construction of the pGL3-Control-CDK2 and pGL3-Control-PAF plasmids was described previously [11], and the corresponding mutants were generated by deleting the “seed sequence” of the miR-200b binding site, i.e. CAGUAUU, which was performed by GenScript. Get A Quote

摘要

miR-200b is a pleiotropically acting microRNA in cancer progression, representing an attractive therapeutic target. We previously identified miR-200b as an invasiveness repressor in esophageal squamous cell carcinoma (ESCC), whereas further understanding is warranted to establish it as a therapeutic target. Here, we show that miR-200b mitigates ESCC cell growth by inducing G2-phase cell cycle arrest and apoptosis. The expression/activation of multiple key cell cycle regulators such as CDK1, CDK2, CDK4 and Cyclin B, and the Wnt/β-Catenin signaling are modulated by miR-200b. We identified CDK2 and PAF (PCNA-associated factor), two important tumor-promoting factors, as direct miR-200b targets in ESCC. Correlating... More

关键词